dc.contributorUniversidade Estadual Paulista (Unesp)
dc.contributorUniversidade de São Paulo (USP)
dc.date.accessioned2018-11-26T17:06:44Z
dc.date.available2018-11-26T17:06:44Z
dc.date.created2018-11-26T17:06:44Z
dc.date.issued2016-10-01
dc.identifierPharmacological Research. London: Academic Press Ltd- Elsevier Science Ltd, v. 112, p. 49-57, 2016.
dc.identifier1043-6618
dc.identifierhttp://hdl.handle.net/11449/162068
dc.identifier10.1016/j.phrs.2016.01.031
dc.identifierWOS:000385595100005
dc.identifierWOS000385595100005.pdf
dc.description.abstractG protein-coupled receptors (GPCRs) are the most important targets for drug discovery and not surprisingly similar to 40% of all drugs currently in the market act on these receptors. Currently, one of the most active areas in GPCRs signaling is biased agonism, a phenomenon that occurs when a given ligand is able to preferentially activate one (or some) of the possible signaling pathways. In this review, we highlight the most recent findings about biased agonism, including an extension of this concept to intracellular signaling, allosterism, strategies for assessment and interpretation, and perspectives of therapeutic applications for biased agonists. (C) 2016 Elsevier Ltd. All rights reserved.
dc.languageeng
dc.publisherElsevier B.V.
dc.relationPharmacological Research
dc.relation1,811
dc.rightsAcesso aberto
dc.sourceWeb of Science
dc.subjectGPCR
dc.subject7TMR
dc.subjectFunctional selectivity
dc.titleRecent updates on GPCR biased agonism
dc.typeArtículos de revistas


Este ítem pertenece a la siguiente institución